Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2015

View Archived Issues

Merck & Co. describes discovery of novel DGAT2 inhibitors

Discovery and optimization of novel HIV integrase inhibitors from BMS

DelMar Pharmaceuticals receives additional funding to develop VAL-083

Novartis gives details on early testing of potent BCR-ABL allosteric inhibitor

Omeros reports additional data from phase II trial of OMS-721

Novel SYK inhibitor shows antitumor activity in preclinical models

FDA accepts filing of supplemental BLA for Keytruda

New translocator protein ligands target mitochondrial dysfunction in Alzheimer's disease

Bristol-Myers Squibb patents factor XIa and KLKB1 inhibitors

TUBE Pharmaceuticals discloses cytotoxic compounds for cancer

Roche develops PDE10A inhibitors

FDA approves first treatment for hypoactive sexual desire disorder in women

Enanta Pharmaceuticals designs anti-HCV agents

Remedy Pharmaceuticals starts pilot trial of Cirara for spinal cord injury

Theravance Biopharma patent discloses NEP inhibitors

Biohaven acquires ALS Biopharma glutamate signaling modulator portfolio

FDA awards QIDP status to Matinas BioPharma's encochleated amphotericin B

Kadimastem's astrocyte therapy increases survival in animal model of ALS

Lilly launches Humalog U-200 KwikPen in U.S.

Intarcia reports results from ITCA-650 phase III trial FREEDOM-2

NantKwest starts phase II trial of NK-92 in Merkel cell carcinoma

Peptide drug developer Phoundry Pharmaceuticals completes financing

Phase II study examines combination of pembrolizumab and IL-12 gene therapy in melanoma

Biogen announces ALS genomics collaboration

Bavarian Nordic initiates first-in-human study of RSV vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...